International Clinical Trial: A Prospective, Single-Arm, Multicenter Clinical Study of Furmonertinib Combined with Brain Radiotherapy in the Treatment of EGFR-Mutant Non-Small Cell Lung Cancer with Leptomeningeal Metastasis

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133734) titled 'A Prospective, Single-Arm, Multicenter Clinical Study of Furmonertinib Combined with Brain Radiotherapy in the Treatment of EGFR-Mutant Non-Small Cell Lung Cancer with Leptomeningeal Metastasis' on Oct. 4.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: He'nan Provincial Cancer Hospital

Condition: Non-small cell lung cancer

Intervention: Experimental group:Furmonertinib combined with radiotherapy. Furmonertinib: 160 mg orally once daily Brain radiotherapy: SRT: 20-40 Gy/1-5 fractions WBRT: 30 Gy/3 Gy/10 fractions

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollm...